Drug Trial Radar · NCT02901184
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Last checked: Nov 20, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Nov 23, 2017
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Uppsala UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Karolinska University; Duke Clinical Research Institute; National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Sep 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) suggest spironolactone may be effective in HFPEF, but it is generic and will not be studied by industry. SPIRRIT is a unique Registry-Randomized Clinical Trial (RRCT) that will test the hypothesis that spironolactone plus standard of care compared to standard of care alone reduces the composite of CV mortality and HF hospitalization as follows: Population: HFPEF patients in the Swedish Heart Failure Registry and HFPEF patients in US. HFPEF defined as symptoms/signs of HF, elevated NTproBNP (B-type Natriuretic Peptide; N-terminal pro b-type Natriuretic Peptide) and EF\>=40%. Intervention and control: Randomized 1:1 to intervention: spironolactone + usual care vs. control: usual care alone. Outcome: Primary outcome cardiovascular death or time to HF hospitalization. Secondary outcomes include hospitalization for various causes, adverse events and treatment adherence. In Sweden outcomes are obtained automatically by linking with the Population, Patient and Drug Dispensed Registries. In the US, outcomes will be reported by sites and supplemented by data from a call center. The trial is event-driven with enrollment 7 years and study duration 9 years. For the primary outcome (CV Death or first HF hospitalization) with an event target of 721 events the sample size requires 1985 patients conservatively rounded to approximately 2000 patients.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
SpironolactoneDrug
Treatment with Spironolactone tablets on top of standard care
Standard careOther
Standard care does not involve Spironolactone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence rate for total heart failure (HF) hospitalizations or cardiovascular (CV) deathTime frame: Collected at data base lock, five (5) years after study start (US: continuously until 5 years after study start)
Locations
78 sites in 2 countries. Site status is shown where the registry gives one.
Advanced Cardiovascular LLC
Alexander City, Alabama · Terminated
University of Alabama at Birmingham
Birmingham, Alabama · Terminated
Banner - University Medical Group
Tucson, Arizona · Terminated
MedStar Cardiovascular Research Network
Washington D.C., District of Columbia · Terminated
Howard University Hospital
Washington D.C., District of Columbia · Terminated
Holy Cross Hospital
Fort Lauderdale, Florida · Terminated
Piedmont Atlanta Hospital
Atlanta, Georgia · Terminated
Wellstar Health System, Inc.
Marietta, Georgia · Terminated
Queens Medical Center
Honolulu, Hawaii · Terminated
Fox Valley Clinical Research Center, LLC
Aurora, Illinois · Terminated
University of Illinois at Chicago
Chicago, Illinois · Terminated
Alexian Brothers Medical Center
Elk Grove Village, Illinois · Terminated
Methodist Medical Center of Illinois
Peoria, Illinois · Terminated
St. Vincent Medical Group
Indianapolis, Indiana · Terminated
Ochsner Medical Center
New Orleans, Louisiana · Terminated
Shady Grove Adventist Hospital
Rockville, Maryland · Terminated
Brigham and Women's Hospital
Boston, Massachusetts · Terminated
Pentucket Medical Associates
Haverhill, Massachusetts · Terminated
Charles River Medical Associates
Natick, Massachusetts · Terminated
Newton-Wellesley Hospital
Newton, Massachusetts · Terminated
University of Michigan Medical Center
Ann Arbor, Michigan · Terminated
Ascension Genesys Hospital
Grand Blanc, Michigan · Terminated
The Heart House Haddon Heights
Haddon Heights, New Jersey · Terminated
Rutgers University - Robert Wood Johnson Medical School
New Brunswick, New Jersey · Terminated
University of New Mexico Health Science Center
Albuquerque, New Mexico · Terminated
University at Buffalo
Buffalo, New York · Terminated
Northwell Health - Manhasset
Manhasset, New York · Terminated
Mount Sinai Medical Cente
New York, New York · Terminated
Mid Carolina Cardiology Research
Charlotte, North Carolina · Terminated
Duke University
Durham, North Carolina · Terminated
University of Cincinnati Medical Center
Cincinnati, Ohio · Terminated
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania · Terminated
Jefferson University Hospital
Philadelphia, Pennsylvania · Terminated
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania · Terminated
Stern Cardiovascular Center
Germantown, Tennessee · Terminated
Baylor University Medical Center
Dallas, Texas · Terminated
University of Miami Hospital
Miami, Texas · Terminated
University of Texas Health Science Center at San Antonio
San Antonio, Texas · Terminated
Hälsostaden Ängelholms sjukhus
Ängelholm, Sweden · Terminated
Angereds närsjukhus
Angered, Sweden · Terminated
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.